Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
Black Rock Inc. New York, NY14.7MShares$629 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$510 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$461 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$264 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$122 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.72MShares$117 Million2.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.63MShares$112 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.5MShares$107 Million5.18% of portfolio
-
Vestal Point Capital, LP New York, NY2.35MShares$101 Million6.55% of portfolio
-
Pictet Asset Management Sa Geneva 73, V82.25MShares$96.5 Million0.09% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 29
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.18%
|
$200,000
$40.96 P/Share
|
|
Apr 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$76,000
$38.11 P/Share
|
|
Apr 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
Apr 21
2025
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
20,000
-44.6%
|
$760,000
$38.46 P/Share
|
|
Apr 21
2025
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.84%
|
$120,000
$6.21 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
3,190
-4.59%
|
$121,220
$38.66 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+22.34%
|
$120,000
$6.21 P/Share
|
|
Apr 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+1.23%
|
$12,312
$38.56 P/Share
|
|
Apr 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+2.12%
|
$12,312
$38.56 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
551
+0.82%
|
$20,938
$38.56 P/Share
|
|
Apr 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
162
+0.69%
|
$6,156
$38.56 P/Share
|
|
Apr 15
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
162
+0.65%
|
$6,156
$38.56 P/Share
|
|
Apr 10
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.17%
|
$180,000
$36.77 P/Share
|
|
Apr 08
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$72,000
$36.18 P/Share
|
|
Apr 08
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
Apr 07
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,886
-4.27%
|
$101,010
$35.78 P/Share
|
|
Apr 03
2025
|
Robert Arthur Harrington Director |
SELL
Open market or private sale
|
Direct |
450
-2.98%
|
$17,550
$39.43 P/Share
|
|
Mar 31
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
15,000
-3.39%
|
$600,000
$40.75 P/Share
|
|
Mar 19
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Bona fide gift
|
Direct |
200
-0.14%
|
-
|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$86,000
$43.58 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 386K shares |
|---|---|
| Exercise of conversion of derivative security | 287K shares |
| Open market or private sale | 535K shares |
|---|---|
| Payment of exercise price or tax liability | 11K shares |
| Bona fide gift | 2.16K shares |